Isentress 400 mg, 25 mg and 100 mg FC tablet, chewable tablet
PDF Leaflet Revision Date: 21 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in patients 2 years and older.
Dosage (summary)
Adults: 400 mg twice daily; Children: weight-based dosing for chewable tablets.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use in pregnancy considered safe; breastfeeding not recommended.
Key Drug Interactions
- Aluminium and magnesium antacids
- Rifampicin
- Atazanavir
Contraindications
- Hypersensitivity to components
- Breastfeeding
Common side effects
- Diarrhoea
- Nausea
- Headache
- Fatigue
- Rash
Counselling Points
- Take with or without food
- Monitor for severe rash
- Avoid antacids close to dosing
Serious warnings
- Severe skin reactions
- Immune reconstitution syndrome
Important Disclaimer
The Isentress 400 mg, 25 mg and 100 mg FC tablet, chewable tablet professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
